Physician profile
Benedicto M Estoesta
NPI 1649451071
$21,999.13
in general payments reported to CMS, 2019-2025
56 companies · $3,083 in 2025
The $3,083 reported for 2025 was more than what 96% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,416 · 2020: $3,135 · 2021: $3,210 · 2022: $2,728 · 2023: $3,057 · 2024: $3,370 · 2025: $3,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,415 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,415.35 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,452.53 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Astrazeneca Pharmaceuticals Lp | $1,809.79 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,482.70 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $1,343.86 | 2019-2025 | |
| Mylan Specialty L.P. | $1,316.60 | 2019-2024 | Yupelri |
| Amgen INC. | $1,289.15 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $1,219.86 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,120.42 | 2019-2024 | Xarelto |
| Antares Pharma, INC. | $863.44 | 2019-2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $671.37 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $590.24 | 2019-2025 | |
| Exact Sciences Corporation | $549.14 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $545.13 | 2019-2023 | Seglentis, Livalo |
| Corcept Therapeutics | $484.42 | 2019-2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $450.06 | 2019-2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benedicto Estoesta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.